# Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer

> **NCT04828395** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 65 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Camrelizumab
- **DRUG:** Fluzoparib
- **DRUG:** Cisplatin，Pemetrexed
- **DRUG:** Cisplatin，Etoposide
- **DRUG:** Carboplatin, Albumin Paclitaxel
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT04828395
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2023-03-01
- **Final completion:** 2025-03-01
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2021-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04828395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04828395, "Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04828395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*